What's new? Log in Free sign up

Table search / International Stem Cell Corporation / "Research and Development"

17 results

Newest first Best match first

ISCO International Stem Cell Corporation

Quarterly report

		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Product sales		$	2,179			$	1,973			$	6,639			$	5,900
Operating expenses:
Cost of sales			974				781				2,774				2,318
General and administrative			816				832				2,609				2,550
Selling and marketing			292				302				928				926
Research and development			187				155				447				345
Total operating expenses			2,269				2,070				6,758				6,139
Loss from operations			(90)				(97)				(119)				(239)
Other income (expense):
Interest expense			(35)				(34)				(106)				(105)
Other income			—				—				5				8
Employee retention credit			—				—				—				663
Total other income (expense), net			(35)				(34)				(101)				566
Net income (loss)			(125)				(131)				(220)				327
Undistributed earnings allocated to participating securities			—				—				—				(155)
Net income (loss) allocable to common stockholders		$	(125)			$	(131)			$	(220)			$	172
Net income (loss) per common share, basic and diluted		$	(0.02)			$	(0.02)			$	(0.03)			$	0.02
Weighted-average common shares used to compute net income (loss) per share, basic and diluted			8,004,389				8,004,389				8,004,389				8,004,389

13 Nov 24

4:00pm

ISCO International Stem Cell Corporation

Quarterly report

The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023 (in thousands, except percentages):

		Three Months Ended September 30,
		2024				2023				$ Change				% Change
Product sales		$	2,179			$	1,973			$	206				10	%
Cost of sales			974				781				193				25	%
Profit margin			1,205				1,192				13				1	%
As a % of revenues			55	%			60	%
General and administrative			816				832				(16)				-2	%
Selling and marketing			292				302				(10)				-3	%
Research and development			187				155				32				21	%
Other expense, net			(35)				(34)				(1)				3	%
Net income		$	(125)			$	(131)			$	6				-5	%
As a % of revenues			-6	%			-7	%

13 Nov 24

4:00pm

ISCO International Stem Cell Corporation

Quarterly report

The following table summarizes our results of operations for the nine months ended September 30, 2024 and 2023 (in thousands, except percentages):

		Nine Months Ended September 30,
		2024				2023				$ Change				% Change
Product sales		$	6,639			$	5,900			$	739				13	%
Cost of sales			2,774				2,318				456				20	%
Profit margin			3,865				3,582				283				8	%
As a % of revenues			58	%			61	%
General and administrative			2,609				2,550				59				2	%
Selling and marketing			928				926				2				0	%
Research and development			447				345				102				30	%
Other income (expense), net			(101)				566				(667)				-118	%
Net income (loss)		$	(220)			$	327			$	(547)				-167	%
As a % of revenues			-3	%			6	%

13 Nov 24

4:00pm

ISCO International Stem Cell Corporation

Quarterly report

Total stock-based compensation expense recorded in the condensed consolidated statements of operations is as follows (in thousands):

		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Cost of sales		$	—			$	1			$	2			$	3
General and administrative			71				92				268				261
Selling and marketing			—				1				2				4
Research and development			29				24				94				66
Total		$	100			$	118			$	366			$	334

13 Nov 24

4:00pm

ISCO International Stem Cell Corporation

Quarterly report

The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023 (in thousands, except percentages):

		Three Months Ended June 30,
		2024				2023				$ Change				% Change
Product sales		$	2,331			$	1,841			$	490				27	%
Cost of sales			913				713				200				28	%
Profit margin			1,418				1,128				290				26	%
As a % of revenues			61	%			61	%
General and administrative			884				918				(34)				-4	%
Selling and marketing			302				309				(7)				-2	%
Research and development			83				45				38				84	%
Other income (expense)			(30)				636				—				0	%
Net income		$	119			$	492			$	(373)				-76	%
As a % of revenues			5	%			27	%

13 Aug 24

4:00pm

0mgm9eovk1wrrr22a9

Quarterly report

13 Aug 24

4:00pm

Quarterly report

13 Aug 24

4:00pm

Quarterly report

13 Aug 24

4:00pm

fabtp pcbo9o09edy4

Quarterly report

13 Aug 24

4:00pm

Quarterly report

14 May 24

4:00pm

Quarterly report

14 May 24

4:00pm

Quarterly report

14 May 24

4:00pm

28 Mar 24

4:30pm

28 Mar 24

4:30pm

28 Mar 24

4:30pm

28 Mar 24

4:30pm

28 Mar 24

4:30pm

Prev
1
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.